Impact of decentralised, community-led molecular STI point-of-care testing on testing practices in remote First Nations communities in Australia
Annie Tangey, Kirsty Smith, Belinda Hengel, Kelly Andrewartha, Handan Wand, Amit Saha, Jessica Leonard, Manoji Gunathilake, Lorraine Anderson, Donna B Mak, Steven Badman, David Persing, Basil Donovan, Lisa Maher, Susan Matthews, Christopher K Fairley, Mark Shephard, John Kaldor, Rae-Lin Huang, James Ward, Rebecca Guy, Louise CauserObjective
In remote Australia, where there is a substantial burden of sexually transmitted infections (STIs) among First Nations peoples, testing and timely treatment are key to reducing prevalence. We evaluated the impact of introducing molecular point-of-care (POC) testing for chlamydia/gonorrhoea and later trichomonas on STI testing (including syphilis) and positive tests.
Methods
We conducted a retrospective interrupted time-series analysis of routinely collected data from First Nations peoples aged 15–54 years attending 20 remote/regional clinics participating in the Test, Treat and GO programme (2016–2019). We used segmented regression models to estimate the immediate level change (first month of POC) and after-period trends in monthly tests, positive tests and proportion of concurrent syphilis tests to assess sustainability. Before and after comparisons were estimated using linear regression models.
Results
There were 17 437 chlamydia/gonorrhoea and 14 173 trichomonas tests performed, mostly among women (69% and 64%) and individuals aged 15–34 years (72% and 68%). Following the introduction of molecular POC testing, there were immediate level increases in monthly tests: chlamydia/gonorrhoea by 26% (+154, p<0.001) and trichomonas by 21% (+116, p=0.004) and level increases of positive tests: gonorrhoea by 30% (+13, p=0.017) and trichomonas by 29% (+14, p=0.034); chlamydia was unchanged. The proportion of chlamydia/gonorrhoea tests with concurrent syphilis tests remained unchanged (−1.7%; −0.9%; p=0.531), while the proportion increased among positive chlamydia/gonorrhoea tests by 25% (+13%; p=0.013). Increased levels of testing were sustained for gonorrhoea/chlamydia (+2.7, p=0.118) and trichomonas (−3.5, p=0.400) and syphilis among those with positive chlamydia/gonorrhoea tests (−0.2%, p=0.593).
Conclusion
Molecular POC testing led to immediate and sustained increases in STI testing and an immediate increase in positive tests in remote primary care. The use of POC testing is likely to result in earlier diagnosis and treatment and reduced onward transmission and sequelae, supporting a broader integration of POC testing in high-burden settings.